Hemodialysis does not appear to have a substantial impact on apixaban exposure [see Clinical Pharmacology (12.3)]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid)...
The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively. Bleedin...
The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively. Bleedin...
Other agents and hemodialysis do not have a significant effect. Implementation Implementation Implementation High Alert: Do not confuse apixaban with axitinib. When converting from warfarin , discontinue warfarin and start apixaban when INR is <2.0. When converting from apixaban to warfarin , apixaban ...
ESRD maintained on hemodialysis: 5 mg BID; decrease dose to 2.5 mg BID if 1 additional characteristic of age ≥80 years or weight ≤60 kg is present Postoperative Prophylaxis of DVT/PE Indicated following hip or knee replacement surgery Initial: Give 2.5 mg PO 12-24 hr after surgery Duration...
Hemodialysis does not appear to have a substantial impact on apixaban exposure [seeCLINICAL PHARMACOLOGY]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in indivi...
Hemodialysis does not appear to have a substantial impact on apixaban exposure [seeCLINICAL PHARMACOLOGY]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in indivi...
Hemodialysis does not appear to have a substantial impact on apixaban exposure [seeCLINICAL PHARMACOLOGY]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in indivi...
Hemodialysis does not appear to have a substantial impact on apixaban exposure [seeCLINICAL PHARMACOLOGY]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in indivi...
Hemodialysis does not appear to have a substantial impact on apixaban exposure [seeCLINICAL PHARMACOLOGY]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in indivi...